Supernus Pharmaceuticals Receivables 2011-2024 | SUPN
Supernus Pharmaceuticals receivables from 2011 to 2024. Receivables can be defined as the total amount of collectibles for a company
Supernus Pharmaceuticals Annual Receivables
(Millions of US $) |
| 2023 |
$144 |
| 2022 |
$165 |
| 2021 |
$149 |
| 2020 |
$141 |
| 2019 |
$87 |
| 2018 |
$103 |
| 2017 |
$66 |
| 2016 |
$42 |
| 2015 |
$26 |
| 2014 |
$17 |
| 2013 |
$5 |
| 2012 |
$1 |
| 2011 |
$ |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Receivables
(Millions of US $) |
| 2024-09-30 |
$145 |
| 2024-06-30 |
$152 |
| 2024-03-31 |
$148 |
| 2023-12-31 |
$144 |
| 2023-09-30 |
$142 |
| 2023-06-30 |
$137 |
| 2023-03-31 |
$144 |
| 2022-12-31 |
$165 |
| 2022-09-30 |
$164 |
| 2022-06-30 |
$158 |
| 2022-03-31 |
$145 |
| 2021-12-31 |
$149 |
| 2021-09-30 |
$134 |
| 2021-06-30 |
$137 |
| 2021-03-31 |
$127 |
| 2020-12-31 |
$141 |
| 2020-09-30 |
$133 |
| 2020-06-30 |
$127 |
| 2020-03-31 |
$119 |
| 2019-12-31 |
$87 |
| 2019-09-30 |
$87 |
| 2019-06-30 |
$85 |
| 2019-03-31 |
$80 |
| 2018-12-31 |
$103 |
| 2018-09-30 |
$78 |
| 2018-06-30 |
$75 |
| 2018-03-31 |
$68 |
| 2017-12-31 |
$66 |
| 2017-09-30 |
$56 |
| 2017-06-30 |
$51 |
| 2017-03-31 |
$39 |
| 2016-12-31 |
$42 |
| 2016-09-30 |
$36 |
| 2016-06-30 |
$34 |
| 2016-03-31 |
$31 |
| 2015-12-31 |
$26 |
| 2015-09-30 |
$24 |
| 2015-06-30 |
$18 |
| 2015-03-31 |
$19 |
| 2014-12-31 |
$17 |
| 2014-09-30 |
$15 |
| 2014-06-30 |
$11 |
| 2014-03-31 |
$10 |
| 2013-12-31 |
$5 |
| 2013-09-30 |
$8 |
| 2013-06-30 |
$1 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
